Results 21 to 30 of about 25,411 (262)

Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: A systematic review and meta-analysis [PDF]

, 2016
Background: Hypertension and proteinuria are critically involved in the progression of chronic kidney disease. Despite treatment with renin angiotensin system inhibition, kidney function declines in many patients.
Boesby, L. (Lene), Currie, G. (Gemma), Delles, C. (Christian), Edwards, N.C. (Nicola C.), Ferro, C.J. (Charles J.), Fujita, T. (Toshiro), Jardine, A.G. (Alan G.), Lindhardt, M. (Morten), Mark, P.B. (Patrick B.), Meiracker, A.H. (Anton) van den, Ohtsu, H. (Hiroshi), Oveisi, S. (Sonia), Preiss, D.J. (David J.), Rossing, K., Saklayen, M.G. (Mohammad G.), Taylor, A.H.M. (Alison H. M.), Townend, J. (Jonathan)   +16 more
core   +1 more source

Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction:findings from BIOSTAT-CHF [PDF]

, 2017
Aims Mineralocorticoid receptor antagonists (MRAs) are recommended (unless contraindicated) to all patients with heart failure with reduced ejection fraction (HFrEF). However, MRAs are still largely underused in routine clinical practice.
Agrinier, Albert, Azizi, Bostick, Bozkurt, Cooper, Curtis, Dev, Dev, Dickstein, Elze, Epstein, Erhardt, Eschalier, Ferreira, Fonarow, Ghali, Gheorghiade, Hernandez, Juurlink, Kalidindi, Lachaine, Lam, Levey, Maggioni, Maggioni, Maggioni, Margolis, Masoudi, McMurray, Olivier, Pitt, Pitt, Pitt, Ponikowski, Postmus, Raebel, Rossignol, Rossignol, Rossignol, Shah, Takeda, Vardeny, Vardeny, Voors, Williams, Williams, Zannad, Zannad, Zannad   +49 more
core   +8 more sources

Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably! [PDF]

, 2017
No abstract ...
Aspirin Myocardial Infarction Study Research Group, Baigent, Baigent, Bonaca, Chin, Cleland, Cleland, Cleland, Cleland, Cleland, Cleland, Gelder, Homma, Lewis, Massie, Meune, Michel, Pitt, Pitt, Silva, Solomon, Tweeddale, Zannad, Zannad   +23 more
core   +1 more source

Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism

Frontiers in Endocrinology, 2021
ObjectiveTo investigate how often target renin is pursued and achieved in patients with primary aldosteronism (PA) and other low renin hypertension (LRH) treated with mineralocorticoid receptor antagonists (MRAs), as reversal of renin suppression was ...
Yuta Tezuka, Yuta Tezuka, Adina F. Turcu
doaj   +1 more source

Effect of the glucocorticoid receptor antagonist Org 34850 on fast and delayed feedback of corticosterone release [PDF]

, 2007
We investigated the effect of the glucocorticoid receptor (GR) antagonist Org 34850 on fast and delayed inhibition of corticosterone secretion in response to the synthetic glucocorticoid methylprednisolone (MPL).
Craighead, Mark, Grassie, Morag, Harrison, Louse R., Lightman, Stafford L., MacSweeney, Cliona P., Spiga, Francesca, Thomson, Fiona .J., Wood, Susan A.   +7 more
core   +1 more source

Comparison of different strategies to measure medication adherence via claims data in patients with chronic heart failure [PDF]

, 2019
Medication adherence correlates with morbidity and mortality in patients with chronic heart failure (CHF), but is difficult to assess. We conducted a retrospective methodological cohort study in 3,808 CHF patients, calculating adherence as proportion of ...
Griese‐Mammen, Nina, Ihle, Peter, Krueger, Katrin, Laufs, Ulrich, Parrau, Natalie, Schubert, Ingrid, Schulz, Martin   +6 more
core   +1 more source

Mineralocorticoid receptor antagonists for heart failure [PDF]

Expert Opinion on Pharmacotherapy, 2011
Although mineralocorticoid receptor (MR) antagonists are indicated in systolic heart failure, they are underprescribed in patients with appropriate indications for their prescription and often used in those in whom the evidence for probable benefit is scant.
openaire   +4 more sources

Rational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: review

Consilium Medicum, 2022
Mineralocorticoid receptor antagonists (MRAs) are part of basic medical therapy for heart failure. The clinical efficacy of MRAs has been proven by randomized clinical trials. To review comparative efficacy and tolerability data between the two main MRAs,
Natalia V. Safronova, Igor V. Zhirov, Sergey N. Tereshchenko   +2 more
doaj   +1 more source

Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling [PDF]

, 2015
Type 2 diabetes (DM2) increases the risk of cardiovascular disease. Aldosterone, which has pro-oxidative and pro-inflammatory effects in the cardiovascular system, is positively regulated in DM2.
Bruder-Nascimento, Thiago, Cau, Stefany B.A., Fais, Rafael S., Lopes, Rheure A.M., Mestriner, Fabiola L.A.C., Silva, Marcondes A.B., Tostes, Rita C., Touyz, Rhian M.   +7 more
core   +3 more sources

Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice

Frontiers in Physiology, 2022
Obesity and/or metabolic diseases are frequently associated with chronic kidney disease and several factors associated with obesity may contribute to proteinuria and extracellular matrix production.
Roberto Palacios-Ramirez, Ixchel Lima-Posada, Benjamin Bonnard, Marie Genty, Amaya Fernandez-Celis, Judith Hartleib-Geschwindner, Fabienne Foufelle, Natalia Lopez-Andres, Krister Bamberg, Frederic Jaisser, Frederic Jaisser   +10 more
doaj   +1 more source